XWARSNT
Market cap395mUSD
Dec 20, Last price
189.40PLN
1D
-0.73%
1Q
4.64%
Jan 2017
1,099.49%
IPO
2,229.64%
Name
Synektik SA
Chart & Performance
P/E
30.80
P/S
3.61
EPS
6.15
Div Yield, %
0.32%
Shrs. gr., 5y
—
Rev. gr., 5y
5.99%
Revenues
625m
+39.82%
Net income
85m
+61.36%
CFO
88m
-6.79%
Dividend
Mar 01, 20243.03 PLN/sh
Earnings
Feb 12, 2025
Profile
Synektik Spólka Akcyjna provides products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine applications in Poland. The company sells medical equipment used in diagnostics and therapy, and nuclear medicine; the development of IT solutions used in radiology; and produces and sells radiopharmaceutical products used in diagnostics for oncology. It also operates a research laboratory for diagnostic imaging systems and a service center for medical equipment. In addition, the company offers maintenance services for medical equipment, as well as acceptance and specialist tests. Synektik Spólka Akcyjna was founded in 2001 and is based in Warsaw, Poland.
Valuation
Title PLN in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑09 | 2023‑09 | 2022‑09 | 2021‑09 | 2020‑09 | 2019‑09 | 2018‑09 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
| Income | |||||||||||
Revenues | 624,797 39.82% | 446,872 167.81% | 166,861 29.72% | ||||||||
Cost of revenue | 500,630 | 377,605 | 156,846 | ||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | 124,166 | 69,267 | 10,015 | ||||||||
NOPBT Margin | 19.87% | 15.50% | 6.00% | ||||||||
Operating Taxes | 20,090 | 13,223 | 1,988 | ||||||||
Tax Rate | 16.18% | 19.09% | 19.85% | ||||||||
NOPAT | 104,076 | 56,044 | 8,027 | ||||||||
Net income | 84,636 61.36% | 52,452 409.18% | 10,301 22.87% | ||||||||
Dividends | (25,843) | (5,117) | (3,838) | ||||||||
Dividend yield | 0.99% | 1.62% | |||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | 4,967 | 4,873 | 23,670 | ||||||||
Long-term debt | 42,032 | 31,269 | 28,223 | ||||||||
Deferred revenue | 1 | ||||||||||
Other long-term liabilities | 24,392 | 26,908 | 22,916 | ||||||||
Net debt | (37,333) | (28,047) | 40,810 | ||||||||
| Cash flow | |||||||||||
Cash from operating activities | 88,079 | 94,493 | |||||||||
CAPEX | (43,129) | (9,685) | |||||||||
Cash from investing activities | (33,027) | (11,547) | |||||||||
Cash from financing activities | (33,383) | (31,596) | 2,143 | ||||||||
FCF | 71,351 | 68,168 | (10,958) | ||||||||
| Balance | |||||||||||
Cash | 84,332 | 63,466 | 10,857 | ||||||||
Long term investments | 724 | 227 | |||||||||
Excess cash | 53,092 | 41,846 | 2,740 | ||||||||
Stockholders' equity | 132,047 | 74,625 | 87,165 | ||||||||
Invested Capital | 186,912 | 137,984 | 143,833 | ||||||||
ROIC | 64.07% | 39.77% | 6.81% | ||||||||
ROCE | 50.30% | 37.13% | 6.50% | ||||||||
| EV | |||||||||||
Common stock shares outstanding | 8,529 | 8,529 | |||||||||
Price | 191.80 216.50% | 60.60 117.59% | 27.85 -5.91% | ||||||||
Market cap | 516,865 117.59% | 237,536 -5.91% | |||||||||
EV | 488,818 | 278,346 | |||||||||
EBITDA | 140,523 | 84,048 | 22,054 | ||||||||
EV/EBITDA | 5.82 | 12.62 | |||||||||
Interest | 4,352 | 1,903 | 1,456 | ||||||||
Interest/NOPBT | 3.50% | 2.75% | 14.54% | ||||||||